VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Core Insights - VolitionRx Limited has secured €2.0 million (approximately $2.3 million) in non-dilutive funding from regional government agencies in Belgium to support its ongoing development efforts [1][2]. Funding Details - The financing will be utilized for the development of the Nu.Q® product portfolio, including the regulatory transition program for Nu.Q® NETs and the research and development of a Lateral Flow product aimed at improving access in Low Income Countries [2]. - The total non-dilutive funding received by Volition to date exceeds $25 million, with this latest funding being part of a strategy to seek favorable terms for cash support [3][4]. Strategic Goals - The funding aims to enhance Volition's manufacturing capabilities and strengthen its research and development activities in Wallonia, Belgium [3]. - Key value inflection points targeted by this financing include clinical validation and the expansion of commercialization efforts for Volition's technologies [3]. Company Overview - VolitionRx is focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancers and conditions associated with NETosis [4]. - The company is developing cost-effective blood tests that have the potential to enhance patient outcomes and quality of life through earlier detection [4].